Tci GeneROCO:6879 65 Current Ratio is 9.27 as of Dec. 2025, which is 35% above its 10-year median of 6.87. GuruFocus rates ROCO:6879 with a GF Score™ of 65/100 and a GF Value™ of NT$49.18 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 1,410 Biotechnology companies, Tci Gene ranks better than 75.67% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Tci Gene's current ratio for the quarter that ended in Dec. 2025 was 9.27.
Tci Gene has a current ratio of 9.27. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Tci Gene's Current Ratio or its related term are showing as below:
ROCO:6879'
s Current Ratio Range Over the Past 10 Years
Min: 2.61 Med: 6.87 Max: 9.82
Current: 9.27
During the past 7 years, Tci Gene's highest Current Ratio was 9.82. The lowest was 2.61. And the median was 6.87.
ROCO:6879's Current Ratio is ranked better than 75.67% of 1410
companies
in the Biotechnology industry
Industry Median: 3.89
vs ROCO:6879: 9.27
Tci Gene (ROCO:6879) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Tci Gene Current Ratio Related Terms
Tci Gene Current Ratio Historical Data
* Premium members only.
The historical data trend for Tci Gene's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6879 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Tci Gene's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tci Gene Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tci Gene's Current Ratio distribution charts can be found below:
* The bar in red indicates where Tci Gene's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tci Gene (ROCO:6879) has a Current Ratio of 9.27 as of Dec. 2025. This is 35% above median its historical median of 6.87. Over the past decade, Tci Gene's Current Ratio has ranged from 2.61 to 9.82. According to the industry distribution chart, Tci Gene ranks #343 out of 1410 companies in the Biotechnology industry, placing it in the top 24.3%.
Is Tci Gene's Current Ratio too high?
Tci Gene's current Current Ratio of 9.27 is 35% above median its 10-year median of 6.87. Over the past 10 years, this metric has ranged from a low of 2.61 to a high of 9.82. The Biotechnology industry median Current Ratio is 3.89. Tci Gene's value of 9.27 is 138.3% above this industry median. Based on the distribution chart, Tci Gene ranks #343 out of 1410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Tci Gene has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tci Gene's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Tci Gene ranks #343 out of 1410 companies for Current Ratio. This places Tci Gene in the top 24% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Tci Gene's value of 9.27 is 138.3% above this benchmark. Historically, Tci Gene's own Current Ratio has ranged from 2.61 to 9.82 over the past decade. While the company's 10-year median is 6.87 vs. the industry median of 3.89, Tci Gene has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tci Gene's current Current Ratio of 9.27 is 138.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tci Gene's current Current Ratio is 9.27, which is 35% above median its own 10-year median of 6.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tci Gene stock overvalued right now?
Based on GuruFocus' analysis, Tci Gene (ROCO:6879) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$49.18, compared to a current price of NT$37.00 — trading 24.8% below its estimated fair value. The current Current Ratio is 9.27, which is 35% above median its 10-year median of 6.87 and 138.3% above the Biotechnology industry median of 3.89. Tci Gene's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Tci Gene (ROCO:6879), the current Current Ratio is 9.27 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tci Gene (ROCO:6879) Overvalued in 2026?
Based on GuruFocus' analysis, Tci Gene stock appears to be undervalued.
The current stock price of NT$37.00 is trading 24.8% below its estimated GF Value™ of NT$49.18.
GuruFocus considers Tci Gene to be Modestly Undervalued.
Key valuation signals for ROCO:6879:
Current Ratio: 9.27 (35% above median its 10-year median of 6.87)
GF Value™: NT$49.18 vs. price of NT$37.00 (24.8% below fair value)
Industry Position: 138.3% above the Biotechnology median (#343 of 1410)
No single metric tells the full story. See the ROCO:6879 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tci Gene Inc provides precision preventive medicines in Taiwan. It is the first to introduce the concept of precision preventive medicine with Predict prediction, Prevent prevention, and Personal Treatment personalized health management measures.
65GF Score
Get the complete analysis for ROCO:6879
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6879 has been successfully added to your 
